Sanofi 4Q EPS Beats, Sales Miss; Sees 2016 EPS Broadly Stable
(Bloomberg) -- Co. sees 2016 Business EPS “broadly stable” y/y at constant FX, barring unexpected major events.
- 4Q net sales: EU9.28b vs est. EU9.38b
- Business EPS: EU1.31 vs est. EU1.28
- Business net income: EU1.71b vs est. EU1.68b
- Div. EU2.93 vs BDVD est. EU3
- 4Q division sales at constant FX:
- pharma: EU7.28b, down 4.7% y/y
- diabetes: EU1.9b, down 13% y/y
- Genzyme: EU1.01b, up 28% y/y
- Consumer Health: EU809m, up 1% y/y
- Vaccines: EU1.44b, up 15% y/y
- Animal Health: EU559m, up 5.9% y/y
- 4Q drug sales:
- Lantus: EU1.54b vs est. EU1.67b
- Plavix: EU455m vs est. EU433.3m
- Lovenox: EU419m vs est. EU430m
- Fabrazyme: EU158m vs est. EU149.2m
- Cerezyme: EU180m vs est. EU213.1m
- Toujeo: EU98m vs est. EU77.1m
- Aubagio: EU272m vs est. EU252.1m
- Aprovel: EU170m vs est. EU164.9m
- Apidra: EU104m vs est. EU101m
- Praluent: EU5m
- NOTE: Yday, PREVIEW SANOFI 4Q: Expectations Low as One-Time Items to Weigh
Alert:
HALISTERSource: BFW (Bloomberg First Word)
Tickers SAN FP (Sanofi)
To de-activate this alert, click
hereUUID: 7947283